Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-exendin PET imaging of pancreatic beta cells after remission of type 2 diabetes following bariatric surgery
2014-004317-90Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of 68Ga-NODAGA-Exendin-4 in type 2 diabetes mellitus (T2DM) and carbohydrate malabsorption (2 arms), sponsored by Radboud University Medical Center. Started Jan 2015; status: completed.
02
Drugs
68Ga-NODAGA-Exendin-4
03
Conditions
type 2 diabetes mellitus (T2DM)carbohydrate malabsorption
Beyond the preview
Go deeper on 2014-004317-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004317-90.